LRLeila Rahbarnia

Leila Rahbarnia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Leila Rahbarnia has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Computational Design Of A Peptide Candidate Targeting NOTCH1 And PI3K/AKT Signaling Pathways In Cancer: A Coarse-Grained Molecular Dynamics Simulation Study

    by Soheila ParcheBafieh, Shiva Khezri, Habib Zarredar, Leila Rahbarnia, Safar Farajnia

    The PI3K/AKT and NOTCH1 signaling pathways are key regulators of tumor progression, proliferation, survival, and metastasis in numerous cancers, making them attractive targets for peptide-based anticancer therapies. Dermaseptin-B2 is a well-characterized anticancer peptide known to modulate the PI3K/AKT signaling pathway; however, its therapeutic application may be limited by suboptimal cellular uptake. In contrast, Magainin-2 exhibits strong membrane-interacting and cell-penetrating properties and has been widely employed in the development of hybrid bioactive peptides to enhance membrane permeability and intracellular delivery. In this study, a peptide library was constructed from truncated fragments of Dermaseptin-B2 and Magainin-2 to identify hybrid peptides targeting the PI3K/AKT and NOTCH1 signaling pathways. A five-amino-acid anticancer motif derived from Dermaseptin-B2 was fused to a ten-amino-acid membrane-active fragment of Magainin-2 to improve cellular penetration. Subsequently, three rational amino acid substitutions were introduced into the lead peptide (MD3)—lysine replacing phenylalanine, histidine replacing glycine, and valine replacing serine—to enhance anticancer activity, optimize cell penetration, and reduce potential toxicity. Molecular docking analyses demonstrated favorable binding of MD3 to proteins involved in the PI3K/AKT and NOTCH1 signaling pathways. Molecular dynamics simulations, including RMSD, RMSF, and radius of gyration analyses, confirmed the structural stability of the peptide–protein complexes throughout the simulation period. Binding free-energy calculations using the MM-PBSA method indicated thermodynamically favorable interactions between MD3 and its target proteins. Furthermore, analyses of hydrogen-bond distance and angle distributions supported the formation of stable, geometrically favorable intermolecular interactions. Coarse-grained membrane simulations further demonstrated the efficient membrane-penetrating capability of MD3 in a DOPS–DOPC lipid bilayer model. Collectively, these findings identify MD3 as a promising multifunctional hybrid peptide that targets multiple cancer-associated signaling pathways and exhibits favorable membrane penetration and structural stability, highlighting its potential as a candidate for future peptide-based anticancer therapeutics.

  • In Silico Design and Structural Characterization of 4D5mocB-PE24: A Novel Immunotoxin for EpCAM-Targeted Cancer Therapy

    by Fatemeh Heidari, Safar Farajnia, Reza Salahlou, Hossein Babaei, Leila Rahbarnia

    Introduction: Antibody-based immunotoxins are a promising novel therapeutic approach aimed at targeted cancer therapy, utilizing the target specificity of antibody fragments attached to a potent cytotoxic molecule. Oportuzumab monatox, an EpCAM-specific immunotoxin, has shown clinical activity in Non-Muscle-Invasive Bladder Cancer (NMIBC) but is limited by its high immunogenicity. To address this limitation, we developed a novel construct comprising the 4D5mocB antibody fragment fused to a truncated, deimmunized Pseudomonas aeruginosa exotoxin A. Methods: Various bioinformatics methods were employed to assess physicochemical characteristics and analyze structural stability using Molecular Dynamics (MD) simulations. The predicted epitope content for B cells and T cells, as well as the binding affinity for the EpCAM receptor, were also evaluated and compared with that of the parental immunotoxin. Results: Molecular dynamics analysis showed that the 4D5mocB-PE24 immunotoxin rapidly stabilized within 10 ns, maintaining RMSD values of 0.5-0.7 nm, whereas the PE40-based complex exceeded 2.0 nm after 22 ns. Moreover, computational modeling of the truncation and deimmunization process reduced the predicted number of B- and T-cell epitopes by 56% and 43%, respectively, and markedly decreased MHC class II binding. Discussion: These findings demonstrate that epitope deletion and rational mutagenesis substantially reduce predicted immunogenicity while preserving high target-binding affinity; however, these findings will require experimental validation. Conclusion: This study identifies 4D5mocB-PE24 as a promising anti-EpCAM immunotoxin candidate with reduced immunogenicity, supporting further preclinical and clinical evaluation for EpCAM-positive cancers.

  • Rational Design of a Novel Anti-Cancer Hybrid Peptide Inhibiting the PI3K/AKT and CDK2 Signaling Pathways using Molecular Dynamics Simulations

    by Hannaneh Zare, Leila Rahbarnia, Mohammad Pazhang, Reza Salahlou

    Melittin (MLT) peptide is considered due to targeting key proteins involved in apoptosis pathways to suppress tumor progression. However, the clinical application of MLT is limited due to its high cytotoxicity and poor cellular permeability. In this study, a hybrid peptide (AM1) derived from MLT and Aurein 1.2(Aur1.2) with modified properties was designed to enhance its therapeutic efficacy. A truncated form of MLT comprised of the last five C-terminal amino acids, was fused to a modified truncated Aur 1.2, in which Glycine was replaced with Tyrosine to enhance anticancer properties. Based on docking results, AM1 indicated specific interaction with the AKT1 protein in, Glu278, Asp292, and Thr308 residues. Also, it showed a specific interaction with residues Glu51, Asp86, and Asp145 in CDK2 protein. According to VMD results, the N-terminal region of the Aur1.2 peptides, excluding the first three amino acids, maintained its α-helical structure up to 50 ns. However, at 100 ns, partial structural alterations were observed, such that only amino acids 7 to 12, corresponding to the Aur region, retained their α-helical conformation. RMSD and RMSF analyses revealed no significant or undesirable fluctuations throughout the simulation of 200 ns of molecular dynamics. The RMSD values for the AM1 peptide ranged between 0.00048 and 0.64 nm and reached stability after 140 ns. Additionally, RMSD and RMSF analyses confirmed the stability of the AKT1–AM1 and CDK2–AM1 complexes. DSSP analysis indicated that the secondary structures of both complexes remained stable throughout the simulations. In addition, MM/GBSA calculations demonstrated that the binding of AM1 to both proteins is thermodynamically favorable, indicating stable and effective interactions. Furthermore, CG simulation results demonstrated the ability of the AM1 peptide to penetrate the DOPC-DOPS model membrane. In silico results suggest that AM1 is a candidate inhibitor of the PI3K/AKT and CDK2 signaling pathways, which are crucial in cancer progression; however, this finding still needs experimental validation.


  • The Computational and Experimental Study of M1 and M2 Peptides Combined with Vancomycin to Control Vancomycin-Intermediate Enterococcus faecalis

    by Ali Bahadori, Khalil Maleki Chollou, Leila Rahbarnia, Somayeh Nabizadeh

    Melittin (MLT), an antimicrobial peptide, is considered due to its wide range of antimicrobial properties against Gram-negative and Gram-positive bacteria. In this study, we performed in silico and in vitro studies for the evaluation of the synergistic effect of M1 and M2 peptides derived from MLT to limit vancomycin intermediate E. faecalis. Results obtained from coarse-grained simulations indicated significant destruction during the penetration of the M1 and M2 peptides into the E. faecalis membrane model. The trajectory results also revealed notable movements of 2.381 nm and 2.758 nm within the membrane for M1 and M2 peptides, respectively. The synergistic effect of MLT, M1, and M2 peptides with vancomycin was evaluated to inhibit the growth of a VIE clinical isolate using the established checkerboard method. MTT assays and hemolysis tests were conducted to examine the toxicity of the peptides. The combination therapy of vancomycin with the peptides led to an 80-fold reduction in the MIC value of vancomycin (from 8 to 0.125 µg/ml). In contrast, it led to a 13.33-fold reduction in the MIC value of MLT, an eightfold decrease in the MIC value of both M1 and M2 peptides. Based on FICI values, a synergistic effect was observed between MLT, M1, and M2 with vancomycin. MTT assay and hemolysis results indicated a notable reduction in the toxicity of the peptides at the synergistic concentrations. In conclusion, the combination therapy of MLT and M1 and M2 peptides with the vancomycin antibiotic could be an appealing therapeutic strategy against E. faecalis infections.

  • Phage Display as a Medium for Target Therapy Based Drug Discovery, Review and Update

    by Samaneh Jahandar-Lashaki, Safar Farajnia, Aref Faraji-Barhagh, Zahra Hosseini, Nasim Bakhtiyari, Leila Rahbarnia

    Phage libraries are now amongst the most prominent approaches for the identification of high-affinity antibodies/peptides from billions of displayed phages in a specific library through the biopanning process. Due to its ability to discover potential therapeutic candidates that bind specifically to targets, phage display has gained considerable attention in targeted therapy. Using this approach, peptides with high-affinity and specificity can be identified for potential therapeutic or diagnostic use. Furthermore, phage libraries can be used to rapidly screen and identify novel antibodies to develop immunotherapeutics. The Food and Drug Administration (FDA) has approved several phage display-derived peptides and antibodies for the treatment of different diseases. In the current review, we provided a comprehensive insight into the role of phage display-derived peptides and antibodies in the treatment of different diseases including cancers, infectious diseases and neurological disorders. We also explored the applications of phage display in targeted drug delivery, gene therapy, and CAR T-cell. Graphical Abstract


  • Critical Point Mutations in the RBD of SARS-COV-2 Involved in Binding to ACE2

    by Milad Tolouie, Safar Farajnia, Davoud Farajzadeh, Leila Rahbarnia, Ali Rabbizadeh Saray

    The spike protein of SARS-CoV-2 plays an essential role in viral pathogenesis. It binds to human cells' angiotensin-converting enzyme 2 (ACE2) receptor

  • Open Access

    The high cross-transmission in methicillin resistant Staphylococcus aureus between healthy and patient communities

    by Behnood Haji Sheikhzadeh, Leila Rahbarnia, Alireza Dehnad, Behrooz Naghili, Parvaneh Saffarian

    Background and Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) is one of the main causes of high mor- tality and morbidity in hospitals. This study was aimed to examine virulence factors, molecular typing, and the antibiotic resistance pattern of MRSA isolates in hemodialysis patients and healthy communities. Materials and Methods: Total of 231 and 400 nasal samples were obtained from hemodialysis patients and healthy com- munities, respectively. Virulence factors profile was examined in two groups by PCR reaction. Enterobacterial Repetitive Intergenic Consensus (ERIC-PCR) was used as a molecular typing approach. Results: Overall, 35.49% (82/231) of hemodialysis patients were positive for S. aureus, and 47.56% (39/82) of isolates were positive for mecA. In a healthy community, 15% (60/400) of samples were positive for S. aureus, and 36.66% (22/60) were positive for mecA. The frequency of MDR was significantly higher in patients group (p-value < 0.00001). The frequency of pvl (p.value = 0.003932, P<0.05) and tsst-1 (p.value = 0.003173, p < .05) were significantly higher in patients group. The highest frequency virulence factors in healthy individuals were related to hla (68.33%, 41/60), hlb (53.33%, 32/60), and Acme/arcA (46.66%) genes. Two groups were clustered by the ERIC-PCR method into 7 clusters and 2 single isolate with a 0.74 similarity index. Based on the results, each cluster was combination with healthy and patient isolates. Conclusion: Our findings indicate a notable variation in the frequency of virulence factors between S. aureus isolates ob- tained from dialysis patients and the healthy community.

  • Open Access

    Correction to: Design of a hybrid peptide derived from melittin and CXCL14 –C17: a molecular dynamics simulation study

    by Safar Farajnia, Leila Rahbarnia, Nazli Khajehnasiri, Habib Zarredar


  • The Synthetic Antimicrobial Peptide Derived From Melittin Displays Low Toxicity and Anti-infectious Properties

    by Parisa Mansouri Rad, Leila Rahbarnia, Azam Safary, Azizeh ShadiDizaji, Zahra Maani

    The low stability and nonspecific toxicity are the main limiting factors for the clinical applications of melittin (MLT). This study aimed to design and synthesize new analogs of MLT to increase stability, reduce toxicity, and retain their antimicrobial properties against bacterial pathogens. At first, peptide analogs were designed computationally by inducing single mutations in MLT peptides and evaluating their physicochemical properties. The stability of the analogs with the highest scores was determined by Gromacs software. In vitro assays were performed to examine the antimicrobial activity and toxicity of the selected analogs. Two peptide analogs, M1 and M2, were selected based on the SVM score in cell PPD. The M1 analog was created by replacing alanine with leucine on the 15th. The M2 analog was designed by substituting alanine with leucine and isoleucine with arginine at the 15th and 17th positions. According to the Gromacs results, the M2 peptide indicated more stability. RMSD and RMSF results showed no undesirable fluctuations during the 200 ns MD simulation. The MIC and MBC values for the M1 peptide were calculated in a range of 8–128 μg/ml, while the M2 peptide limited the bacterial growth to 32–128 μg/mL. Both peptides indicated less toxicity than natural MLT, based on MTT assay results. The hemolytic activity of the M1 analog was more than M2 at 16 μg/mL concentration. M1 peptide displayed the highest selectivity index against S. aureus and A. baumannii, which were approximately 5.27-fold improvements compared to MLT. In conclusion, we introduced two analogs of MLT with low toxicity, low hemolytic activity, and higher stability, along with retaining antimicrobial properties against gram-negative and positive bacteria.


  • Rational design of an anti-cancer peptide inhibiting CD147 / Cyp A interaction

    by Zahra Maani, Safar Farajnia, Leila Rahbarnia, Elaheh Zadeh Hosseingholi, Nazli Khajehnasiri, Parisa Mansouri